Angie Purvis, LLC

ADLM 2026 highlighted a innovations in diagnostics in the areas of precision medicine, advanced biomarkers, and AI‑driven analytics. The integration of these tools is rapidly becoming core drivers of clinical and operational performance. Modernizing laboratory workflows and integrating intelligent diagnostic technologies is now a strategic imperative for competitive advantage for innovators in diagnostics and healthcare.

I’m heading to San Francisco this week for the 33rd Annual Tri-Con Precision Medicine Innovation Conference—an event that reflects the future of diagnostics, drug development, and data-driven healthcare. This year’s theme, Entering the Age of AI, couldn’t be more timely. I’m especially energized by the advancements emerging across precision medicine, including liquid biopsy biomarkers for MRD and MCED, AI‑enabled drug development, next‑generation at‑home and point‑of‑care dia

After my most recent post , I received many questions about the different types of blood‑derived specimen collection, preservation, and transport systems. One theme stood out: confusion about how these systems differ and what those differences mean from a regulatory and test performance standpoint. Innovation Is Transforming Blood Collection Over the past decade, specimen collection technologies have evolved rapidly. Many of these innovations are patient‑centered by design, a

Your diagnostic test is only as strong as its specimen collection kit. Rushed or poorly designed kits lead to errors, delays, and regulatory risk. A thoughtful, compliant kit protects your brand and ensures accurate results. If you're preparing a launch or update, now is the time to verify design, instructions, and classification. Strong kits build strong diagnostics!